Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Quince Therapeutics, Inc.
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
August 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
June 25, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
June 03, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
May 06, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
April 01, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Launches Scientific Advisory Board
February 22, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
February 15, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Participate at Investor Events in January 2024
January 04, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
October 23, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
September 28, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
September 06, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
August 10, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
July 24, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
April 11, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
April 06, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
April 05, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
March 22, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
January 30, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
January 27, 2023
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury
September 16, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications
September 12, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures
August 30, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Present at Upcoming Scientific Meetings
August 25, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022
August 04, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Tickers
QNCX
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
August 01, 2022
From
Quince Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.